Sanofi’s Post

PD-1 inhibitors are a type of anticancer drug that block the activity of PD-1, a protein on immune cells called T cells. 👉 PD-1 normally acts as an "off switch" to keep T cells from attacking other cells. 👉 However, some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack. 👉 PD-1 inhibitors can block this binding and boost the immune response against cancer cells.

so honored being engaged in the obtaining approval in EU

A groundbreaking treatment for Type 2 diabetes may eliminate the need for insulin injections, offering new hope for patients. In a recent clinical trial, 86% of participants were able to stop using insulin after just a few weeks of therapy. The innovative treatment combines an existing drug, semaglutide, with a novel procedure known as re-cellularization via electroporation therapy https://lnkd.in/eyy3CHXE FuturistSpeaker.com #foresight #predictions #futuretrends #futureofwork #futurejobs #keynotespeaker #futuriststrategy #mostquoted

Each year in the United States, 185,000 individuals experience recurrent strokes. (1) 😱 Let's not just scroll past this number. Let's take action! Spread awareness, learn the warning signs, and prioritize preventive care. Every step counts in the fight against strokes! 💪💙 Find out how the rapid Genomadix CYP2C19 test can help optimize DAPT treatment to reduce recurrent stroke rates at www.genomadixcom (2,3)🧬#StrokeAwareness #PersonalizedMedicine #Pharmacogenetics 1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467. 2. Wang Y, et al. N Engl J Med. 2021;385:2520-2530. 3. Lee CR, et al. J Clinical Pharmacol Therapeutics. 2022;122(5):959-967.

Thanks to Gary Rafaloff and co-authors, including others living with Parkinson's and researchers like Brian Fiske, for creating a digestible summary of where the Parkinson's clinical trial pipeline currently stands. I appreciate that the pipeline includes nearly 60% symptomatic (easing the motor and non-motor symptoms) but more than 40% disease-modifying (impacting the underlying disease to slow or stop progression over time) therapies. And that there is diversity in treatment approaches (inflammation, mitochondria, cell pathways, etc.), especially in the disease-modifying portfolio. Check out the full paper for details: https://shorturl.at/NJyQG

📣 Exciting update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (IV psilocin) for major depression.   ELE-101 is an intravenous formulation of psilocin designed to provide consistent and controllable drug delivery. As the active metabolite of psilocybin, psilocin has the potential to offer a rapid onset, significantly shorter treatment duration and reduced variability between patients, compared to oral formulations of psilocybin. This could enhance convenience and therapeutic outcomes for patients with depression while reducing the resource burden on healthcare systems   Today’s news release shares initial results from the Phase 1 part of the study and announces that the first patients have been dosed in the Phase 2a part.   Full press release here: https://lnkd.in/e4UfBhgg

Very exciting update on ATAI Life Sciences AG's and Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a patent-protected, intravenous formulation of psilocin, which is the active moiety in the body when psilocybin is administered orally. As such, I view ELE-101 as a relatively de-risked asset for its stage of development, as it leverages the robust proof-of-concept data that has been established with psilocybin across multiple trials. Especially, it has the potential to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter (!) treatment paradigm of less than 2 hours. So much larger TAM/business upside. #psychedelics #investing #future

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis : Genentech, a member of the Roche Group, announced that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options. “Ocrevus Zunovo gives patients and providers another option for receiving Ocrevus, building on a decade of robust safety and efficacy data for Ocrevus in multiple sclerosis,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “Today’s approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs.”  For further reading : https://t.co/X1sWLsHryX

In an interview with The Clinical Trial Vanguard’s Moe Alsumidaie, Elysium Therapeutics, Inc. CEO Greg Sturmer discusses O2P, a groundbreaking path to #painrelief that’s designed to help reduce the risk of opioid misuse. #opioidoverdose #opioidepidemic #painmedication #opioidmisuse #elysiumtherapeutics #hydrocodone https://lnkd.in/eUnapmfJ

In a phase III #paroxysmalnocturnalhemoglobinuria clinical trial, #crovalimab produced efficacy that was noninferior to #eculizumab and with a "positive benefit-risk profile:" #PNH, #Heme https://lnkd.in/eSUPNckA